VJHemOnc is committed to improving our service to you

ASH 2019 | How to sequence therapies in CLL after venetoclax discontinuation?

VJHemOnc is committed to improving our service to you

Anthony Mato

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale and results of an international retrospective cohort study of the efficacy of therapies following venetoclax discontinuation in chronic lymphocytic leukemia (CLL). Dr Mato highlights that the therapies they were most interested in included bruton tyrosine kinase inhibitors, phosphoinositide 3-kinase inhibitors and cellular therapy (CAR-T or allo-HSCT). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter